OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to assess the safety and tolerability of arimoclomol over six months of treatment in patients with ALS who participated in the phase IIa double-blind study (AALS-001). The secondary objective is to evaluate the long-term effect of arimoclomol on the ALS-specific functional rating scale (ALSFRS-R) and forced vital capacity (FVC) in patients with ALS.